Chimeric antigen receptor (CAR) T cell therapy Tecartus receives conditional marketing authorisation for treatment of relapsed or refractory mantle cell lymphoma (MCL)

Conditional authorisation covers patients who have already received ≥2 lines of systemic therapy, including a BTK inhibitor. In phase II ZUMA-2 trial, overall response rate observed in 93% of 60 patients, with 67% of those patients achieving a complete response.

Source:

PharmaTimes